5101-00-8

Usage

Uses

Used in Pharmaceutical Research:
4-(3,4,5-TRIMETHOXYPHENYL)-4-OXOBUTYRIC ACID is utilized as a key intermediate in the development of new pharmaceuticals due to its ability to influence the properties of other compounds, potentially leading to the creation of novel drugs with improved therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(3,4,5-TRIMETHOXYPHENYL)-4-OXOBUTYRIC ACID is employed as a building block for the synthesis of complex organic molecules, contributing to the advancement of chemical compounds with specific applications.
Used in Anti-Inflammatory Treatments:
4-(3,4,5-TRIMETHOXYPHENYL)-4-OXOBUTYRIC ACID is studied for its potential use as an anti-inflammatory agent, given its capacity to modulate biological responses that contribute to inflammation, offering a new avenue for the treatment of inflammatory conditions.
Used in Antioxidant Therapies:
4-(3,4,5-TRIMETHOXYPHENYL)-4-OXOBUTYRIC ACID is also being investigated for its antioxidant properties, which could be harnessed to protect cells from oxidative stress and related diseases, thereby serving as a component in antioxidant therapies.
Used in Biological Assays:
4-(3,4,5-TRIMETHOXYPHENYL)-4-OXOBUTYRIC ACID has shown promising results in various biological assays, indicating its potential use in research to understand complex biological processes and to screen for new therapeutic agents.
Used in the Development of Novel Materials:
Due to its unique structural properties, 4-(3,4,5-TRIMETHOXYPHENYL)-4-OXOBUTYRIC ACID is of interest in the development of new materials with specialized characteristics for use in various industries, including pharmaceuticals, materials science, and beyond.

InChI:InChI=1/C13H16O6/c1-17-10-6-8(9(14)4-5-12(15)16)7-11(18-2)13(10)19-3/h6-7H,4-5H2,1-3H3,(H,15,16)

Upstream product

• 64-17-5 ethanol 
• 135595-20-9 4-oxo-4-(3,4,5-trimethoxy-phenyl)-butyronitrile 
• 3044-56-2 ethyl trimethoxybenzoyl acetate 
• 105-36-2 ethyl bromoacetate 
• 180900-30-5 2-(3,5-Bis-benzyloxy-4-methoxy-benzoyl)-4-oxo-4-(3,4,5-trimethoxy-phenyl)-butyric acid ethyl ester 
• 141-52-6 sodium ethanolate 
• 94201-97-5 (E)-4-Oxo-4-(3,4,5-trimethoxy-phenyl)-but-2-enoic acid 
• 1136-86-3 methyl (3,4,5-trimethoxyphenyl) ketone 
• 118-41-2 Eudesmic acid 
• 42924-22-1 3-diethylamino-1-(3,4,5-trimethoxy-phenyl)-propan-1-one 
• 180900-29-2 2-(3-Benzyloxy-4,5-dimethoxy-benzoyl)-4-oxo-4-(3,4,5-trimethoxy-phenyl)-butyric acid ethyl ester 

Downstream Products

• 141916-07-6 4-oxo-4-(3,4,5-trimethoxy-phenyl)-butyric acid methyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluations of 1,2-diaryl pyrroles as analogues of combretastatin A-4

A series of novel 1,2-diaryl pyrroles as analogues of combretastatin A-4 (CA-4, 1a) were synthesized and evaluated for their antitumour potential against three cancer cell lines. Most compounds exhibited growth inhibition against all of the cancer cell lines. Compound 7q not only exhibited prominent antitumour efficacy with IC50 values of 0.390 μm in SGC-7901, 0.070 μm in HT-1080 and 0.045 μm in KB cell lines but also showed low activity with IC50 values of 30.08 μm in normal L929 cell line. Moreover, compound 7q inhibited tubulin polymerization into microtubules and caused microtubule destabilization. A molecular docking study of 7q was performed to determine its binding mode at the colchicine site in the tubulin dimer. 1,2-Diaryl pyrroles as combretastatin A-4 analogues were synthesized and evaluated for anti-proliferative activities. Compound 7q exhibited antitubulin activity.

Method for preparing chiral diphosphines

The invention concerns a method for preparing a compound of formula (1) wherein: A represents naphthyl or phenyl optionally substituted; and Ar1, Ar2independently represent a saturated or aromatic carbocyclic group, optionally substituted.

Asymmetric hydrogenation method of a ketonic compound and derivative

The present invention relates to a process for the asymmetric hydrogenation of a ketonic compound and derivative. The invention relates to the use of optically active metal complexes as catalysts for the asymmetric hydrogenation of a ketonic compound and derivative. The process for the asymmetric hydrogenation of a ketonic compound and derivative is characterized in that the asymmetric hydrogenation of said compound is carried out in the presence of an effective amount of a metal complex comprising as ligand an optically active diphosphine corresponding to one of the following formulae: STR1

Synthesis and PAF antagonist activity of some 2,5-diaryltetrahydrofurans incorporating PAF-like functional groups

This paper describes the synthesis and structure-activity relationships of a series of 2,5-diaryltetrahydrofurans, as specific and potent antagonists at the rabbit washed platelet activating factor (PAF) receptor. The methoxyl groups in the known PAF antagonist L-652,731 were replaced with functional groups present in PAF and in the 'PAF-like' antagonists. Activity was generally retained or enhanced when one aryl ring in L-652,731 was elaborated; however incorporation of these functional groups into both of the aryl rings greatly reduced or abolished activity. These results are discussed in relation to a putative model for the PAF receptor.